CION Ameerpet
If your lung cancer carries a specific gene change, the most effective treatment may not be chemotherapy — it may be a tablet aimed precisely at that change. This is targeted therapy. It depends on first knowing your tumour's mutation, because an EGFR-driven cancer, an ALK rearrangement, a ROS1 change, or a KRAS mutation are each matched to different drugs. This guide explains, in plain language, what targeted therapy for lung cancer is, how EGFR and ALK targeted therapy and other oral targeted drugs work, who they suit, and what side effects to expect — so you can make decisions calmly and well-informed.
Targeted therapy is a treatment that blocks a specific gene change driving the cancer, rather than attacking every fast-dividing cell the way chemotherapy does. Some lung cancers grow because a single faulty gene keeps sending a signal to multiply. A targeted drug switches off that signal at its source — so it can act on the cancer while sparing many of the healthy cells around it.
This only works if your tumour carries a change a drug can block. That is why molecular testing — on a tissue sample or, in some cases, a blood test — comes first. The test reads the tumour's gene changes and tells your team whether a matched targeted treatment is an option. Without that information, targeted therapy cannot be chosen safely.
Many lung cancer oral targeted drugs are tablets you take at home, often once a day, rather than infusions in a chemotherapy chair. Because they aim at one target, their side effects are usually different from chemotherapy — and for the right patient, they can control the cancer for a long time.
Targeted therapy is not right for everyone, and it does not replace the conversation with your doctor. It suits lung cancers with a treatable driver mutation — most often a type of non-small cell lung cancer. Your specialist explains whether your tumour qualifies, and why, so the plan makes sense to you.
Different gene changes need different drugs. Below are the targets most often tested for in lung cancer, and what an EGFR ALK targeted therapy or another matched treatment is aimed at. Your report will name which, if any, applies to you.
EGFR is among the most frequently found targets in lung cancer, particularly in non-smokers and in adenocarcinoma. EGFR targeted therapy uses an oral tablet that blocks this signal. Different EGFR changes can need different generations of drug, which is why the exact result matters.
An ALK rearrangement joins part of the ALK gene to another, creating a faulty growth signal. ALK targeted therapy is a tablet designed to block it. ALK-positive lung cancers often respond well, and several matched drugs exist if one stops working over time.
A ROS1 change is less common but very important to find, because ROS1-positive lung cancer can be treated with its own matched oral targeted drugs. Testing for ROS1 is part of standard molecular panels for advanced non-small cell lung cancer.
KRAS was long considered hard to target, but newer drugs can now act on a specific KRAS change (KRAS G12C) in some lung cancers. Whether a KRAS-targeted option fits depends on the exact change found, which is why precise testing matters.
Beyond the main four, several less common changes — such as BRAF, MET, RET, and NTRK — also have matched targeted drugs. A broad molecular panel checks for these, so a treatable target is not missed simply because it is rare.
Many lung cancers have no targetable driver. That is not a setback — it simply means treatment is guided differently, often with chemotherapy, immunotherapy, or a combination. Your team explains the best path for your specific result.
Major guidelines recommend testing every patient with advanced non-small cell lung cancer for a panel of treatable gene changes before choosing first treatment — because matching an oral targeted drug to the right mutation can work very differently from starting general chemotherapy. The single most important step is the molecular test itself: without it, a treatable EGFR, ALK, ROS1, or KRAS target can be missed. (Sources: NCCN Non-Small Cell Lung Cancer guidelines; College of American Pathologists / IASLC / AMP molecular testing guidance.)
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
A short, doctor-led conversation can replace days of anxious searching. We walk this journey with you, from the first question onward.
Targeted therapy is never started on a guess — it follows a clear sequence built around your tumour's molecular result. Here is what usually happens, in order.
A biopsy confirms lung cancer and its type under the microscope. Targeted therapy is mostly relevant in non-small cell lung cancer, so knowing the exact type guides what is tested next.
The tumour is tested for treatable gene changes — EGFR, ALK, ROS1, KRAS and others — using tissue or, in some cases, a blood-based test. This is the step that decides whether targeted therapy is even possible.
If a treatable change is found, your team selects the matched oral targeted drug for it. An EGFR result, an ALK rearrangement, a ROS1 change, or a KRAS mutation each leads to a different choice.
Most targeted drugs are tablets taken at home. You are reviewed regularly with scans and blood tests to check the cancer is responding and to manage any side effects early.
Over time a cancer can find a way around a targeted drug. Repeat testing can reveal a new change, and your team may switch to a different matched drug or another approach. The plan is reviewed, not fixed.
Targeted therapy and chemotherapy are not the same treatment in a different bottle — they work differently, and they feel different. Here is an honest, balanced look at what to expect from lung cancer oral targeted drugs.
Targeted therapy blocks the specific gene change driving the cancer, so it acts on the tumour while sparing many healthy cells. Chemotherapy works more broadly against all rapidly dividing cells.
Many targeted drugs are once-daily tablets taken at home, rather than infusions in hospital. This can mean fewer hospital visits, though regular check-ups and scans are still essential.
Side effects differ from chemotherapy and depend on the drug — they can include skin rash, diarrhoea, mouth soreness, or changes in blood tests. They are usually manageable when watched for and treated early.
For the right patient, a matched targeted drug can keep the cancer in check for a long period. How long varies from person to person, and your team monitors the response closely throughout.
A cancer may eventually adapt and find a way around the drug. This is not a failure on your part; it is expected over time, and repeat testing can guide the next matched treatment.
Whether targeted therapy, chemotherapy, immunotherapy, or a combination is right depends on your mutation result, the stage, and your overall health — discussed openly with you, never rushed.
Because targeted therapy aims at one gene change rather than all dividing cells, its side effects are usually different from chemotherapy. They depend on the specific drug, but common ones can include a skin rash, dry skin, diarrhoea, mouth soreness, and changes in liver blood tests. Most are mild to moderate and tend to settle once your body adjusts or your dose is fine-tuned.
The key is catching and treating side effects early. That is why you are reviewed regularly while on treatment. Simple measures — a moisturiser for the skin, an anti-diarrhoea plan, or a short dose adjustment — often keep things comfortable so you can stay on the medicine that is helping you. You should always report new or worsening symptoms promptly, rather than waiting.
No two people respond identically, and your specialist tailors monitoring to the drug you are on. The goal is to keep the cancer controlled while protecting your quality of life — and every adjustment is explained, with time for your questions, so nothing happens to you without your understanding.
Choosing targeted therapy — and choosing the right drug for your exact mutation — is a decision that should never rest on a single opinion. At CION, your testing and treatment plan is reviewed by a tumour board, a panel of medical, surgical, and radiation oncologists who agree the path together, so every angle is considered before you start.
You sit with a doctor for a 45-minute consultation, with unhurried time to ask what your EGFR, ALK, ROS1, or KRAS result means for you. We order tests step by step and explain each one — no unnecessary tests, and transparent costs from the start. Our team brings 150+ years of combined experience and 17 super-specialist oncologists across 35+ centres in Telangana and Andhra Pradesh, having cared for 15,000+ patients.
Whether your result points to a matched oral targeted drug or to another approach, you have a team that walks this journey with you, making decisions for your healing, not for billing. To understand the wider picture, see our overview of lung cancer at CION, read about the lung cancer diagnosis pathway, learn how a liquid biopsy finds a lung cancer mutation, or explore lung cancer treatment in Hyderabad.
Patients across Telangana and Andhra Pradesh share what it felt like to be heard, examined unhurriedly, and guided with honesty at CION.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Targeted therapy is a treatment that blocks a specific gene change driving the cancer, rather than attacking all fast-dividing cells the way chemotherapy does. Some lung cancers grow because a single faulty gene keeps sending a signal to multiply; a targeted drug switches off that signal at its source, so it can act on the cancer while sparing many healthy cells. This only works if your tumour carries a change a drug can block, which is why molecular testing comes first. Many targeted drugs are tablets taken at home, often once a day, and their side effects are usually different from chemotherapy. Targeted therapy suits lung cancers with a treatable driver mutation — most often a type of non-small cell lung cancer.
The most frequently treated targets are EGFR mutations, ALK rearrangements, ROS1 changes, and certain KRAS mutations, each of which has its own matched oral targeted drug. Beyond these four, several less common changes — such as BRAF, MET, RET, and NTRK — also have matched targeted treatments. A broad molecular panel checks for all of these together, so a treatable target is not missed simply because it is rare. Which target, if any, applies to you depends on the molecular test of your tumour. If no targetable driver is found, that is not a setback — it simply means treatment is guided differently, often with chemotherapy, immunotherapy, or a combination.
EGFR ALK targeted therapy aims at one specific gene change driving the cancer, so it acts on the tumour while sparing many healthy cells. Chemotherapy works more broadly against all rapidly dividing cells in the body. Practically, this means several differences: many targeted drugs are once-daily tablets taken at home rather than infusions in hospital, and their side effects are usually different — they can include skin rash, diarrhoea, or mouth soreness rather than the typical chemotherapy effects. For the right patient, a matched targeted drug can control the cancer for a long time. Which treatment is right for you depends on your mutation result, the stage, and your overall health, and is discussed openly with you.
You are suitable for targeted therapy only if your tumour carries a gene change that a drug can block. That is why molecular testing — on a tissue sample or, in some cases, a blood-based test — comes first and is the deciding step. Targeted therapy is mostly relevant in non-small cell lung cancer, so the exact type of your cancer also matters. If a treatable change such as EGFR, ALK, ROS1, or KRAS is found, your team selects the matched oral targeted drug for it. If no targetable driver is found, targeted therapy is not chosen, and your specialist explains the best alternative path for your specific result. The decision is never made on a guess — it follows your molecular report.
Many lung cancer oral targeted drugs are tablets taken by mouth at home, often once a day, rather than infusions given in a chemotherapy chair. This can mean fewer hospital visits for the treatment itself. However, regular check-ups remain essential — you are reviewed with scans and blood tests to confirm the cancer is responding and to catch any side effects early. Not every targeted treatment is a tablet, and the exact schedule depends on the drug matched to your mutation. Your team explains how to take it, what to watch for, and when to seek help, so you feel confident managing the medicine day to day.
Because targeted therapy aims at one gene change rather than all dividing cells, its side effects are usually different from chemotherapy. They depend on the specific drug but can include a skin rash, dry skin, diarrhoea, mouth soreness, and changes in liver blood tests. Most are mild to moderate and often settle once your body adjusts or your dose is fine-tuned. The key is catching and treating side effects early, which is why you are reviewed regularly while on treatment. Simple measures — a moisturiser for the skin, an anti-diarrhoea plan, or a short dose adjustment — often keep things comfortable. Always report new or worsening symptoms promptly rather than waiting.
Yes — over time a cancer can adapt and find a way around a targeted drug, which is called resistance. This is expected and is not a failure on your part. When it happens, repeat testing can reveal a new gene change behind the resistance, and your team may switch to a different matched targeted drug or move to another approach such as chemotherapy or immunotherapy. For some targets, like ALK, several matched drugs exist so that one can follow another if needed. The treatment plan is reviewed regularly rather than fixed, so it can adapt as your situation changes, always discussed with you before any switch.
At CION, your testing and treatment plan is reviewed by a tumour board — a panel of medical, surgical, and radiation oncologists who agree the path together, so the choice of targeted therapy and the right drug for your mutation are considered from every angle. You sit with a doctor for a 45-minute consultation, with unhurried time to ask what your EGFR, ALK, ROS1, or KRAS result means. Tests are ordered step by step and explained, with no unnecessary tests and transparent costs from the start. Our team brings 150+ years of combined experience and 17 super-specialist oncologists across 35+ centres in Telangana and Andhra Pradesh. The first consultation is free, confidential, and carries no commitment to start treatment.
Browse our complete library of lung cancer guides — symptoms, types, diagnosis, stages, treatment and living with lung cancer.